Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price objective […]
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the sixteen analysts that are presently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a hold recommendation and eleven have given a buy recommendation to the company. The average twelve-month price […]
StockNews.com upgraded shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR – Free Report) from a sell rating to a hold rating in a report issued on Saturday morning. Several other brokerages have also recently weighed in on ARWR. Citigroup started coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, September 19th. They set a neutral rating and […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) Director Victoria Vakiener sold 1,550 shares of the company’s stock in a transaction dated Thursday, September 28th. The stock was sold at an average price of $26.33, for a total transaction of $40,811.50. Following the sale, the director now directly owns 21,734 shares of the company’s stock, […]
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are presently covering the company, MarketBeat reports. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12 month price […]